Control of heart disease risk factors varies widely among outpatient practices, according to a study presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.
[More]
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg.
[More]
Scientists at the Texas Biomedical Research Institute in San Antonio have identified four genes in baboons that influence levels of "bad" cholesterol. This discovery could lead to the development of new drugs to reduce the risk of heart disease.
[More]
The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
[More]
Academic researchers have found that breathing motor vehicle emissions triggers a change in high-density lipoprotein cholesterol, altering its cardiovascular protective qualities so that it actually contributes to clogged arteries.
[More]
Regular marijuana use is associated with favorable indices related to diabetic control, say investigators. They found that current marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, even after excluding patients with a diagnosis of diabetes mellitus. Their findings are reported in the current issue of The American Journal of Medicine.
[More]
Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE.
[More]
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
[More]
Researchers have discovered that participation in physical activity of at least moderate intensity is more critical to childhood cardiometabolic health than overall sedentary time.
[More]
Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.
[More]
CRISPR, a system of genes that bacteria use to defend themselves against viruses, has been found to be involved in helping some bacteria evade the mammalian immune system.
[More]
Researchers at the University of Michigan have identified a new potential therapeutic target for lowering cholesterol that could be an alternative or complementary therapy to statins.
[More]
Despite their greater life expectancy, the adults of today are less "metabolically" healthy than their counterparts of previous generations.
[More]
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.
[More]
Risk prediction tools that estimate future risk of heart disease and stroke may be more useful predictors of future decline in cognitive abilities, or memory and thinking, than a dementia risk score, according to a new study published in the April 2, 2013, print issue of Neurology®, the medical journal of the American Academy of Neurology.
[More]
In what promises to be an eye-opener for many doctors and patients who routinely depend on cholesterol testing, a study led by researchers at the Johns Hopkins University School of Medicine found that the standard formula used for decades to calculate low-density lipoprotein cholesterol levels is often inaccurate.
[More]
UCLA researchers have genetically engineered tomatoes to produce a peptide that mimics the actions of good cholesterol when consumed.
[More]
Cholesterol levels seem to fluctuate significantly with the turning seasons, which may leave some people with borderline high cholesterol at greater cardiovascular risk during the winter months, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Children with acute lymphoblastic leukemia are at risk for developing the metabolic syndrome during maintenance therapy, suggest study findings.
[More]
Current testing strategies for the families of patients with familial hypercholesterolemia may not be an efficient use of health resources, suggest study results published in The Lancet.
[More]